27 December, 2021
One of the big challenges in the treatment of cancer is its heterogeneity. Tumours can present different mutations and change with time, which means that not all treatments are effective or they generate resistance. That’s why it is important to carry out follow-ups that allow us to identify changes as they are produced. However, getting the precise samples to carry out this analysis via a tissue biopsy isn’t always easy. That’s why, in the last few years, a new method has been developed which allows to analyse tumoural DNA circulating in the blood in order to carry out this follow-up and analysis of cancer in an easy and simple way. This is known as liquid biopsy.
10 February, 2021
A new molecular test detects genetic abnormalities in tumours and improves customised cancer diagnosis and treatment
At the Grupo Hospital Clínic, we have a new option for diagnosis of advanced cancer. It is a new test using Next Generation Sequencing (NGS) technology which, by analysing the tumour’s DNA and RNA, detects multiple genetic abnormalities in 52 of your genes. This new cancer diagnostic test allows your treatment to be further customised. In addition, it improves current tests for the diagnosis of lung, colon and rectal cancer and melanoma.
26 September, 2019
From this September, barnaclínic+ Medical Oncology is providing its patients with the best liquid biopsy test currently available for advanced cancer, Guardant-360. Thanks to the agreement between the Medical Oncology and Pathology departments of the Hospital Clínic de Barcelona and the company Guardant Health, the Clínic will be the first centre in Europe to routinely use one of the most advanced liquid biopsy tests on the market.